May 4, 2024 8:00 am EDT MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
May 2, 2024 7:00 am EDT MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
Mar 11, 2024 7:00 am EDT MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
Mar 7, 2024 7:13 am EST Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
Mar 7, 2024 6:00 am EST MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder